Abstract:Objective To investigate the possibility of using melanoma antigen-1 (MAGE-1) peptide as a tumor vaccine to treat hepatocellular carcinoma ( HCC).Methods The expressions of MAGE-1 in 8 HCC cell lines and in liver cancer tissue from a patient were detected using RT-PCR. The type of human leucocyte antigen I (HLA I) of both 8 HCC cell lines and peripheral blood mononuclear cells of the patient was detected using a microcytotoxicity method to screen out target cell lines for the cytotoxicity assay. Peripheral blood mononuclear cells from the HCC patient pulsed with an MAGE-1 pepticle ( NYKCRFPEI) were used as antigen presenting cells. Autogenous peripheral blood mononuclear cells were stimulated with antigen presenting cells every 7 days for 4 times to elicit cytotoxic T lymphocytes. The phenotype of effector cells was analyzed using flow cytometry. The cytotoxicity of effector cells was detected with a lactate dehydrogenase releasing assay.Results The expressions of both MAGE-1 and HLA-A24 were detected in BEL7405 cell line which were used as the positive target cell line in the cytotoxicity assay. The expression of MAGE-1 alone was detected in HLE, BEL7402, BEL7404, QGY7703 and SMMC7721 cell lines, and the expression of neither MAGE-1 nor HLA-A24 was shown in QGY 7701 and HpG2 cell lines. The last 7 cell lines could be used as negative target cell lines in the cytotoxicity assay. Peripheral blood mononuclear cells expanded 32 folds during 28-day culture. The ratio of CD3(+) T cells increased by 16% (from 54% to 70%), and the ratio of CD8(+) T cells increased by 20% (from 36% to 56%) during 28-day culture. When the ratio of effector cells to target cells was 10: 1, effector cells exhibited 62.5% cytotoxicity against autogenous lymphoblasts pulsed with the peptide (NYKCRFPEI) of MAGE-1 antigen, 40.25% cytotoxicity against BEL7405 cells, compared with 17.88% cytolysis observed against autogenous lymphoblasts, 19.55% against HLE cells, and 1.6% against QGY7701 cells. When the ratio of effector cells to target cells was 3. 3:1, the cytotoxicity of effector cells against the peptide pulsed autogenous lymphoblasts was 53.6%, which was much higher against autogenous lymphoblasts, HLE cells and QGY7701 cells at 15.6%, 13% and 1%, respectively.Conclusion The results demonstrate that cytotoxic T lymphocytes with the ability to specifically lyse target cells expressing both MAGE-1 and HLA-A24 could be successfully induced by the MAGE-1 peptide NYKCRFPEI in vitro. This indicates that a good result might be anticipated if this peptide is used as a tumor vaccine to treat HLA-A24 HCC patients.

The Anti-Tumor Immune Response Induced by A Combination of Mage-3/Mage-N-Derived Peptides

Efficacy of MAGE-A4 Long Peptide As a Universal Immunoprevention Cancer Vaccine

Prediction, Synthesis and Identification of HLA-A2-restricted Cytotoxic T Lymphocyte Epitopes of the Tumor Antigen MAGE-n

MAGE-3 peptide amphiphile micelle vaccine promote anti-tumor immunity in mice with stomach cancer

Synthetic Tumor-Specific Antigenic Peptides with a Strong Affinity to HLA-A2 Elicit Anti-Breast Cancer Immune Response Through Activating CD8+ T Cells

Identification of a New MAGE-A10 Antigenic Peptide Presented by HLA-A*0201 on Tumor Cells

Peptide Derived from MAGE-3 Epitope Induced Cytotoxic T Lymphocytes of Hepatocellular Carcinoma Patient in Vitro

Identification of Two Novel Hla-A*0201-Restricted Ctl Epitopes Derived from Mage-A4

[Inhibitory Effect of Dendritic Cells Pulsed with MAGE-3 Peptide on Transplanted Murine Gastric Cancer in Mice].

Preparation and Antitumor Effects of Nanovaccines with MAGE-3 Peptides in Transplanted Gastric Cancer in Mice.

Specific CD8+ T Cell Responses to HLA-A2 Restricted MAGE-A3 P271–279 Peptide in Hepatocellular Carcinoma Patients Without Vaccination

Induction of Cytotoxic T Lymphocytes from the Peripheral Blood of A Hepatocellular Carcinoma Patient Using Melanoma Antigen-1 (Mage-1) Peptide

Identification of Two Naturally Presented MAGE Antigenic Peptides from a Patient with Hepatocellular Carcinoma by Mass Spectrometry.

Prediction and Analysis of HLA-A2/A24-restricted Cytotoxic T-lymphocyte Epitopes of the Tumor Antigen MAGE-n Using the Artificial Neural Networks Method on NetCTL1.2 Server.

Induction of Cytotoxic T Lymphocytes from the Hepatocellular Carcinoma Patients by Using MAGE-3- Gene-Derived and HLA-A2-restricted Peptide

Heat Shock Protein 70 / MAGE-1 Tumor Vaccine Can Enhance the Potency of MAGE-1–specific Cellular Immune Responses in Vivo

[Melanoma Antigen-3 Expression in Human Hepatocellular Carcinoma].

Anti-gastric cancer immunity of MAGE-3 retrogen-transfected dendritic cells

Establishment of antigen MAGE-3 gene vaccine and primary study of its immune activity

Immune Responses to NY--ESO--1 and MAGE--A3 Peptides in Hepatocellular Carcinoma Patients

Heat Shock Protein 70/MAGE-3 Fusion Protein Vaccine Can Enhance Cellular and Humoral Immune Responses to MAGE-3 in Vivo.